Pharmacokinetics and pharmacodynamics of stereoisomeric drugs with particular reference to bioequivalence determination
Identifieur interne : 000225 ( France/Analysis ); précédent : 000224; suivant : 000226Pharmacokinetics and pharmacodynamics of stereoisomeric drugs with particular reference to bioequivalence determination
Auteurs : P. Lees [Royaume-Uni] ; R. P. Hunter [États-Unis] ; P. T. Reeves [Australie] ; P. L. Toutain [France]Source :
- Journal of Veterinary Pharmacology and Therapeutics [ 0140-7783 ] ; 2012-04.
English descriptors
- Teeft :
- Achiral, Achiral assays, Active constituents, Active isomer, Albendazole, Albendazole sulphoxide, Algorithm, Analytical method, Analytical methods, Assay, Bioequivalence, Bioequivalence determination, Bioequivalence studies, Bioequivalence study, Blackwell publishing, Carprofen, Centre, Chiral, Chiral centre, Chiral drug, Chiral drugs, Chiral excipients, Chiral inversion, Chirality, Clinical pharmacology, Cmax, Comparative bioavailability studies, Delatour, Drug development, Drug racemates, Enantiomer, Enantiomeric, Enantiomeric pair, Enantiomeric pairs, Enantiomers exhibit, Enantioselective, European journal, Eutomer, Excipients, Gastrointestinal tract, Ibuprofen, Ibuprofen enantiomers, Individual enantiomers, Inversion, Isomer, Jamali, Ketoprofen, Ketoprofen products, Lees, Metabolic effect, Metabolism, Midha, Nerurkar, Nonchiral, Nonlinear pharmacokinetics, Nonstereoselective, Nonstereoselective assay, Nortriptyline, Optical isomers, Oral dosing, Other hand, Pharmaceutical, Pharmaceutical sciences, Pharmacodynamic, Pharmacodynamics, Pharmacokinetic, Pharmacokinetics, Pharmacological, Pharmacology, Plasma protein binding, Potency ratios, Racemate, Racemates, Racemic, Racemic drugs, Regulatory authorities, Separate enantiomers, Side effects, Single chiral centre, Solubility, Srinivas, Statistical power, Stereochemistry, Stereoisomeric, Stereoisomeric drugs, Stereoisomers, Stereoselective, Stereoselective analysis, Stereoselective assays, Stereoselective methods, Stereoselectivity, Such products, Sulphoxide, Sulphoxide metabolites, Systemic circulation, Therapeutics, Total drug, Toutain, Toxicological, Veterinary, Veterinary interest, Veterinary medicine, Veterinary pharmacology, Whilst.
Abstract
Lees, P., Hunter, R. P., Reeves, P. T., Toutain, P. L. Pharmacokinetics and pharmacodynamics of stereoisomeric drugs with particular reference to bioequivalence determination. J. vet. Pharmacol. Therap.35 (Suppl. 1), 17–29. Drugs containing one or more chiral centres exist in stereoisomeric molecular forms. Most commonly, drugs containing a single asymmetric carbon atom exist in two enantiomeric forms, designated as eutomer (the more potent) and distomer (the less potent). As well as differences in potency and other pharmacodynamic properties, most members of enantiomeric pairs commonly differ also in their pharmacokinetic profiles. This article reviews factors underlying differences in pharmacological properties of enantiomers. The relevance of such differences for studies designed to evaluate the bioequivalence of products containing chiral drugs is also reviewed.
Url:
DOI: 10.1111/j.1365-2885.2012.01367.x
Affiliations:
- Australie, France, Royaume-Uni, États-Unis
- Indiana, Midi-Pyrénées, Occitanie (région administrative)
- Toulouse
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000E42
- to stream Istex, to step Curation: 000E42
- to stream Istex, to step Checkpoint: 000371
- to stream Main, to step Merge: 001363
- to stream Main, to step Curation: 001362
- to stream Main, to step Exploration: 001362
- to stream France, to step Extraction: 000225
Links to Exploration step
ISTEX:428C117F48B2F8ABC37C16C75E0110B71377A2F9Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pharmacokinetics and pharmacodynamics of stereoisomeric drugs with particular reference to bioequivalence determination</title><author><name sortKey="Lees, P" sort="Lees, P" uniqKey="Lees P" first="P." last="Lees">P. Lees</name></author><author><name sortKey="Hunter, R P" sort="Hunter, R P" uniqKey="Hunter R" first="R. P." last="Hunter">R. P. Hunter</name></author><author><name sortKey="Reeves, P T" sort="Reeves, P T" uniqKey="Reeves P" first="P. T." last="Reeves">P. T. Reeves</name></author><author><name sortKey="Toutain, P L" sort="Toutain, P L" uniqKey="Toutain P" first="P. L." last="Toutain">P. L. Toutain</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:428C117F48B2F8ABC37C16C75E0110B71377A2F9</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1111/j.1365-2885.2012.01367.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-XMC9PDDP-S/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000E42</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000E42</idno><idno type="wicri:Area/Istex/Curation">000E42</idno><idno type="wicri:Area/Istex/Checkpoint">000371</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000371</idno><idno type="wicri:doubleKey">0140-7783:2012:Lees P:pharmacokinetics:and:pharmacodynamics</idno><idno type="wicri:Area/Main/Merge">001363</idno><idno type="wicri:Area/Main/Curation">001362</idno><idno type="wicri:Area/Main/Exploration">001362</idno><idno type="wicri:Area/France/Extraction">000225</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Pharmacokinetics and pharmacodynamics of stereoisomeric drugs with particular reference to bioequivalence determination</title><author><name sortKey="Lees, P" sort="Lees, P" uniqKey="Lees P" first="P." last="Lees">P. Lees</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Royal Veterinary College, Hatfield</wicri:regionArea><wicri:noRegion>Hatfield</wicri:noRegion></affiliation></author><author><name sortKey="Hunter, R P" sort="Hunter, R P" uniqKey="Hunter R" first="R. P." last="Hunter">R. P. Hunter</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Food Animal Therapeutics, Elanco Animal Health, Greenfield, IN</wicri:regionArea><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Reeves, P T" sort="Reeves, P T" uniqKey="Reeves P" first="P. T." last="Reeves">P. T. Reeves</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Australian Pesticides and Veterinary Medicines Authority, Canberra, ACT</wicri:regionArea><wicri:noRegion>ACT</wicri:noRegion></affiliation></author><author><name sortKey="Toutain, P L" sort="Toutain, P L" uniqKey="Toutain P" first="P. L." last="Toutain">P. L. Toutain</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Ecole Nationale Veterinaire de Toulouse, 23 Chemin des Capelles 31076, Toulouse</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Veterinary Pharmacology and Therapeutics</title><title level="j" type="sub">Bioequivalence</title><title level="j" type="alt">JOURNAL OF VETERINARY PHARMACOLOGY THERAPEUTICS</title><idno type="ISSN">0140-7783</idno><idno type="eISSN">1365-2885</idno><imprint><biblScope unit="vol">35</biblScope><biblScope unit="issue">s1</biblScope><biblScope unit="page" from="17">17</biblScope><biblScope unit="page" to="29">29</biblScope><biblScope unit="page-count">13</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2012-04">2012-04</date></imprint><idno type="ISSN">0140-7783</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0140-7783</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Achiral</term><term>Achiral assays</term><term>Active constituents</term><term>Active isomer</term><term>Albendazole</term><term>Albendazole sulphoxide</term><term>Algorithm</term><term>Analytical method</term><term>Analytical methods</term><term>Assay</term><term>Bioequivalence</term><term>Bioequivalence determination</term><term>Bioequivalence studies</term><term>Bioequivalence study</term><term>Blackwell publishing</term><term>Carprofen</term><term>Centre</term><term>Chiral</term><term>Chiral centre</term><term>Chiral drug</term><term>Chiral drugs</term><term>Chiral excipients</term><term>Chiral inversion</term><term>Chirality</term><term>Clinical pharmacology</term><term>Cmax</term><term>Comparative bioavailability studies</term><term>Delatour</term><term>Drug development</term><term>Drug racemates</term><term>Enantiomer</term><term>Enantiomeric</term><term>Enantiomeric pair</term><term>Enantiomeric pairs</term><term>Enantiomers exhibit</term><term>Enantioselective</term><term>European journal</term><term>Eutomer</term><term>Excipients</term><term>Gastrointestinal tract</term><term>Ibuprofen</term><term>Ibuprofen enantiomers</term><term>Individual enantiomers</term><term>Inversion</term><term>Isomer</term><term>Jamali</term><term>Ketoprofen</term><term>Ketoprofen products</term><term>Lees</term><term>Metabolic effect</term><term>Metabolism</term><term>Midha</term><term>Nerurkar</term><term>Nonchiral</term><term>Nonlinear pharmacokinetics</term><term>Nonstereoselective</term><term>Nonstereoselective assay</term><term>Nortriptyline</term><term>Optical isomers</term><term>Oral dosing</term><term>Other hand</term><term>Pharmaceutical</term><term>Pharmaceutical sciences</term><term>Pharmacodynamic</term><term>Pharmacodynamics</term><term>Pharmacokinetic</term><term>Pharmacokinetics</term><term>Pharmacological</term><term>Pharmacology</term><term>Plasma protein binding</term><term>Potency ratios</term><term>Racemate</term><term>Racemates</term><term>Racemic</term><term>Racemic drugs</term><term>Regulatory authorities</term><term>Separate enantiomers</term><term>Side effects</term><term>Single chiral centre</term><term>Solubility</term><term>Srinivas</term><term>Statistical power</term><term>Stereochemistry</term><term>Stereoisomeric</term><term>Stereoisomeric drugs</term><term>Stereoisomers</term><term>Stereoselective</term><term>Stereoselective analysis</term><term>Stereoselective assays</term><term>Stereoselective methods</term><term>Stereoselectivity</term><term>Such products</term><term>Sulphoxide</term><term>Sulphoxide metabolites</term><term>Systemic circulation</term><term>Therapeutics</term><term>Total drug</term><term>Toutain</term><term>Toxicological</term><term>Veterinary</term><term>Veterinary interest</term><term>Veterinary medicine</term><term>Veterinary pharmacology</term><term>Whilst</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Lees, P., Hunter, R. P., Reeves, P. T., Toutain, P. L. Pharmacokinetics and pharmacodynamics of stereoisomeric drugs with particular reference to bioequivalence determination. J. vet. Pharmacol. Therap.35 (Suppl. 1), 17–29. Drugs containing one or more chiral centres exist in stereoisomeric molecular forms. Most commonly, drugs containing a single asymmetric carbon atom exist in two enantiomeric forms, designated as eutomer (the more potent) and distomer (the less potent). As well as differences in potency and other pharmacodynamic properties, most members of enantiomeric pairs commonly differ also in their pharmacokinetic profiles. This article reviews factors underlying differences in pharmacological properties of enantiomers. The relevance of such differences for studies designed to evaluate the bioequivalence of products containing chiral drugs is also reviewed.</div></front></TEI><affiliations><list><country><li>Australie</li><li>France</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Indiana</li><li>Midi-Pyrénées</li><li>Occitanie (région administrative)</li></region><settlement><li>Toulouse</li></settlement></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Lees, P" sort="Lees, P" uniqKey="Lees P" first="P." last="Lees">P. Lees</name></noRegion></country><country name="États-Unis"><region name="Indiana"><name sortKey="Hunter, R P" sort="Hunter, R P" uniqKey="Hunter R" first="R. P." last="Hunter">R. P. Hunter</name></region></country><country name="Australie"><noRegion><name sortKey="Reeves, P T" sort="Reeves, P T" uniqKey="Reeves P" first="P. T." last="Reeves">P. T. Reeves</name></noRegion></country><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Toutain, P L" sort="Toutain, P L" uniqKey="Toutain P" first="P. L." last="Toutain">P. L. Toutain</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000225 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000225 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= France
|étape= Analysis
|type= RBID
|clé= ISTEX:428C117F48B2F8ABC37C16C75E0110B71377A2F9
|texte= Pharmacokinetics and pharmacodynamics of stereoisomeric drugs with particular reference to bioequivalence determination
}}
| This area was generated with Dilib version V0.6.33. |  |